Objective: Here we report urodynamic results before and six months after LCIG treatment in PD patients suffering from LUTS.
Background: Dopaminergic transmission plays a key role in regulating urinary activity by acting on the micturition reflex through D1-GABAergic basal ganglia output pathways. Lower urinary tract symptoms (LUTS) have a severe impact on the quality of life in Parkinson’s disease (PD) patients and may benefit from levodopa. Previous studies show that levodopa-carbidopa intestinal gel infusion (LCIG) is associated with improvement in LUTS as measured by clinical scales and urination diaries, suggesting that continuous dopaminergic stimulation might produce stronger effects on micturition than pulsatile stimulation. However, we are unaware of any objective quantification of urinary symptoms in PD patients treated with LCIG.
Method: Three patients (79, 70, and 59 years) underwent the same urodynamic procedure at baseline: placement of a 6-Ch bidirectional bladder catheter, a 10-Ch rectal catheter with subsequent bladder filling with saline at 50 mg/h in the ON condition. Patients were evaluated by the same procedure after 6 months of LCIG therapy.
Results: In Table 1. were summarized urodynamic evaluations. Patient one showed improvement in detrusor overactivity. Patients two and three presented a slight improvement in detrusor hypocontractility, a decrease in incontinence episodes, and a decrease in urethral resistance, respectively.
Conclusion: We observed an improvement in urodynamic parameters in patients with PD after switching from oral therapy to LCIG, associated with improvement in detrusor hyperactivity, detrusor hypocontractility, and urethral resistance. This is the first quantitative analysis of LUTS assessed by objective parameters after switching from pulsatile to continuous dopaminergic therapy
To cite this abstract in AMA style:
D. Rinaldi, O. Voglino, A. Tubaro, FE. Pontieri. Effect of levodopa-carbidopa intestinal gel on lower urinary tract symptoms in Parkinson’s disease: an Urodynamic study [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/effect-of-levodopa-carbidopa-intestinal-gel-on-lower-urinary-tract-symptoms-in-parkinsons-disease-an-urodynamic-study/. Accessed May 20, 2025.« Back to 2022 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/effect-of-levodopa-carbidopa-intestinal-gel-on-lower-urinary-tract-symptoms-in-parkinsons-disease-an-urodynamic-study/